Cargando…

Prediction of the drug–drug interaction potential of the α1‐acid glycoprotein bound, CYP3A4/CYP2C9 metabolized oncology drug, erdafitinib

Erdafitinib is a potent oral pan‐fibroblast growth factor receptor inhibitor being developed as oncology drug for patients with alterations in the fibroblast growth factor receptor pathway. Erdafitinib binds preferentially to α1‐acid glycoprotein (AGP) and is primarily metabolized by cytochrome P450...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Zwart, Loeckie, Snoeys, Jan, Jacobs, Frank, Li, Lilian Y., Poggesi, Italo, Verboven, Peter, Goris, Ivo, Scheers, Ellen, Wynant, Inneke, Monshouwer, Mario, Mamidi, Rao N. V. S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452301/ https://www.ncbi.nlm.nih.gov/pubmed/34273250 http://dx.doi.org/10.1002/psp4.12682

Ejemplares similares

Physiologically‐based pharmacokinetic modeling for primary metabolites of CYP3A and P‐glycoprotein inhibitors in drug–drug interactions: Should we assume the free drug hypothesis?
por: Yamazaki, Shinji, et al.
Publicado: (2022)

Erdafitinib’s effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer
por: Dosne, Anne‐Gaëlle, et al.
Publicado: (2021)

Evaluation of the CYP3A and CYP2B6 Drug‐Drug Interaction Potential of Lemborexant
por: Landry, Ishani, et al.
Publicado: (2021)

Drug-drug interactions: it is not only CYP450's which matter
por: Back, David J
Publicado: (2010)

Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects
por: Fukumura, Kazuya, et al.
Publicado: (2020)

Insights into CYP2B6-mediated drug–drug interactions
por: Hedrich, William D., et al.
Publicado: (2016)

Evaluation of Drug–Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P‐gp Substrates in Patients With an Advanced Solid Tumor
por: Xiao, Jim J., et al.
Publicado: (2018)

Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs
por: Damoiseaux, David, et al.
Publicado: (2022)

Phenotyping Indices of CYP450 and P-Glycoprotein in Human Volunteers and in Patients Treated with Painkillers or Psychotropic Drugs
por: Darnaud, Léa, et al.
Publicado: (2023)

Fluoxetine and norfluoxetine mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19 and CYP3A4
por: Sager, Jennifer E, et al.
Publicado: (2014)

Erdafitinib Resensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs
por: Wu, Chung-Pu, et al.
Publicado: (2020)

Drug–Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes
por: Klomp, Florian, et al.
Publicado: (2020)

Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole
por: Chen, Chiung-Kuang, et al.
Publicado: (2010)

CYP2C8 and antimalaria drug efficacy
por: Gil, JP, et al.
Publicado: (2007)

Drug-induced CYP induction as therapy for tacrolimus intoxication
por: Hoppe, John M., et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug–Drug–Gene Interaction Predictions
por: Loer, Helena Leonie Hanae, et al.
Publicado: (2022)

Drug Strategies Targeting CYP51 in Neglected Tropical Diseases
por: Choi, Jun Yong, et al.
Publicado: (2014)

The Role of CYP450 Drug Metabolism in Precision Cardio-Oncology
por: Fatunde, Olubadewa A., et al.
Publicado: (2020)

Combination Analysis in Genetic Polymorphisms of Drug-Metabolizing Enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese Population
por: Ota, Tomoko, et al.
Publicado: (2015)

Physiologically‐based pharmacokinetic modeling to evaluate in vitro‐to‐in vivo extrapolation for intestinal P‐glycoprotein inhibition
por: Yamazaki, Shinji, et al.
Publicado: (2021)

Investigation into CYP3A4-mediated drug–drug interactions on midostaurin in healthy volunteers
por: Dutreix, Catherine, et al.
Publicado: (2013)

Evaluation of CYP3A‐mediated drug–drug interactions with romidepsin in patients with advanced cancer
por: Laille, Eric, et al.
Publicado: (2015)

Model‐based assessments of CYP3A‐mediated drug‐drug interaction risk of milademetan
por: Hong, Ying, et al.
Publicado: (2021)

Midazolam as a Probe for Heterotropic Drug-Drug Interactions Mediated by CYP3A4
por: Denisov, Ilia G., et al.
Publicado: (2022)

Assessments of CYP‑inhibition‑based drug–drug interaction between vonoprazan and poziotinib in vitro and in vivo
por: Zhou, Shan, et al.
Publicado: (2023)

Corrigendum to: Physiologically‐based pharmacokinetic modeling to evaluate in vitro‐to‐in vivo extrapolation for intestinal P‐glycoprotein inhibition
por: Yamazaki, Shinji, et al.
Publicado: (2022)

CYP2B6 Genotype‐Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers
por: Metzger, Ingrid F., et al.
Publicado: (2019)

Defining the Contribution of CYP1A1 and CYP1A2 to Drug Metabolism Using Humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 Knockout Mice
por: Kapelyukh, Y., et al.
Publicado: (2019)

CYP450 drug inducibility in NAFLD via an in vitro hepatic model: Understanding drug-drug interactions in the fatty liver
por: Rey-Bedon, Camilo, et al.
Publicado: (2022)

Physiologically based pharmacokinetic modeling of tacrolimus for food–drug and CYP3A drug–drug–gene interaction predictions
por: Loer, Helena Leonie Hanae, et al.
Publicado: (2023)

Drug Transport across Porcine Intestine Using an Ussing Chamber System: Regional Differences and the Effect of P-Glycoprotein and CYP3A4 Activity on Drug Absorption
por: Arnold, Yvonne E., et al.
Publicado: (2019)

Molecular docking of azole drugs and their analogs on CYP121 of Mycobacterium tuberculosis
por: Sundaramurthi, Jagadish Chandrabose, et al.
Publicado: (2011)

The Role of CYP2E1 in the Drug Metabolism or Bioactivation in the Brain
por: García-Suástegui, W. A., et al.
Publicado: (2017)

Effects of salidroside on rat CYP enzymes by a cocktail of probe drugs
por: Wei, Yan-Li, et al.
Publicado: (2018)

In Vitro Assessment of CYP-Mediated Drug Interactions for Kinsenoside, an Antihyperlipidemic Candidate
por: Rehman, Shaheed Ur, et al.
Publicado: (2016)

The Fungal CYP51s: Their Functions, Structures, Related Drug Resistance, and Inhibitors
por: Zhang, Jingxiang, et al.
Publicado: (2019)

Impact of CYP2C9‐Interacting Drugs on Warfarin Pharmacogenomics
por: Agrawal, Saaket, et al.
Publicado: (2020)

Interaction between Fexofenadine and CYP Phenotyping Probe Drugs in Geneva Cocktail
por: Bosilkovska, Marija, et al.
Publicado: (2019)

Liquid Biopsies or Therapeutic Drug Monitoring for CYP Activity Profile Determination
por: Pridgeon, Chris S., et al.
Publicado: (2022)

Age-related modifications in CYP-dependent drug metabolism: role of stress
por: Konstandi, Maria, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ds2r4ahf0ugvgotaqv86ts2od9